Inotuzumab ozogamicin versus FLAG-Ida in the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia - real-world resource use data

Leuk Lymphoma. 2020 Feb;61(2):491-493. doi: 10.1080/10428194.2019.1672057. Epub 2019 Oct 3.

Authors

Catherine S Y Lecat¹, Caroline Besley², Rachael E Hough¹, Asim Khwaja³, Caroline Furness², David I Marks², Adele K Fielding³

Affiliations

¹ Department of Haematology, University College London Hospitals, London, UK.
² Bristol Haematology & Oncology Centre, University Hospitals Bristol, Bristol, UK.
³ UCL Cancer Institute, London, UK.

PMID: 31580171
DOI: 10.1080/10428194.2019.1672057

No abstract available

Publication types

Letter

MeSH terms

B-Lymphocytes
Humans
Inotuzumab Ozogamicin
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / epidemiology

Substances

Inotuzumab Ozogamicin